# Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants

> **NCT05517746** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 63 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** BAY2395840 tablet
- **DRUG:** BAY2395840 oral solution
- **DRUG:** Placebo oral solution
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT05517746
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-18
- **Primary completion:** 2020-12-17
- **Final completion:** 2021-03-11
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05517746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05517746, "Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05517746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*